Drug Trial Radar · NCT02421926
Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)
Last checked: Nov 19, 2026Latest source record: Jul 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Oct 2014
Primary completion
May 2023
Study completion May 2023
Sponsor
- Lead sponsor
- Asan Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 21, 2015
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an extension study (prospective observational study) of 'IDEAL' study (A Study to Evaluate Efficacy and Safety of Imatinib (Glinib) 600mg/day depending on Early Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase, NCT02204722) to evaluate the duration of treatment response, disease progression, and survival status up to 5 years after the inclusion.
Conditions
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions
IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)Drug
After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survival rateTime frame: 5-year
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Korea University Ansan Hospital
Ansan, South Korea
Busan National University Hospital
Busan, South Korea
Haeundae Paik Hospital
Busan, South Korea
Chungnam National University Hospital
Daejeon, South Korea
Gachon University Gil Hospital
Incheon, South Korea
Asan Medical Center
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Soonchyunhyang University Hospital
Seoul, South Korea
Ajou University Hospital
Suwon, South Korea
Seoul National University Bundang Hospital
Seongnam, Gyong-gi Province, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.